| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
About ESMO
|
|
|
|
26 |
S8 |
p. v-vi
|
artikel
|
| 2 |
Angiogenic factors and laminin expression in cervical cancer: correlation with treatment response
|
Sharma, M.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 3 |
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study
|
Maio, M.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 4 |
A phase II study combining tremelimumab and durvalumab (MEDI4736) immunomodulating antibodies in mesothelioma patients: The NIBIT-MESO-1 study
|
Calabrò, L.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 5 |
A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with melanoma with brain metastasis: The NIBIT-M2 study
|
Di Giacomo, A.M.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 6 |
A universal killer T-cell for adoptive cell therapy of cancer
|
Wälchli, S.
|
|
|
26 |
S8 |
p. viii1
|
artikel
|
| 7 |
Cell-based immunotherapy combining encapsulation cell technology and irradiated autologous tumor cells: A novel technology platform that is both safe and feasible. Results from first in man trial
|
Mach, N.
|
|
|
26 |
S8 |
p. viii1
|
artikel
|
| 8 |
Combination immunotherapy with oncolytic adenovirus and adoptive T-cell transfer leads to systemic anti-tumor immunity and enhanced therapeutic efficacy in a preclinical melanoma model
|
Tähtinen, S.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 9 |
Correlation between plasma EBV DNA and clinical response to pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma
|
Kao, H.-F.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 10 |
Development of chimeric antigen receptor (CAR) T cells for immunotherapy of glioma
|
Dutoit, V.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 11 |
drug index
|
|
|
|
26 |
S8 |
p. viii15
|
artikel
|
| 12 |
Editorial board
|
|
|
|
26 |
S8 |
p. i-ii
|
artikel
|
| 13 |
Efficacy of anti-CTLA-4 after progression on anti-PD1 therapy in advanced melanoma
|
Moreno, F. Aya
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 14 |
ESMO Symposium on Immuno-Oncology 2015 Officers and Organisation
|
|
|
|
26 |
S8 |
p. vii-viii
|
artikel
|
| 15 |
Expression of immune checkpoint molecules in chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
|
Dufva, O.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 16 |
Five year survival in patients with metastatic melanoma receiving IMM-101
|
Dalgleish, A.G.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 17 |
Hypoxia promotes IL-10 secretion by reactivated CTLs while limiting their expansion
|
de Silly, R. Vuillefroy
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 18 |
Identifying novel cancer antigens using immunoproteomics
|
Smith, M.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 19 |
Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections
|
Wendik, B.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 20 |
Immunomodulatory effects of lenalidomide in combination with gemcitabine as first-line treatment in patients with advanced pancreatic cancer
|
Liljefors, M.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 21 |
Immunomodulatory switch maintenance therapy to improve overall survival in small cell lung cancer (SCLC): The randomized IMPULSE study
|
Thomas, M.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 22 |
Immunotherapy for high-risk neuroblastoma: allogeneic stem cell transplantation and recipient leucocyte infusion
|
de Casterlé, I. Dierckx
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 23 |
Immunotherapy with INO-3112 (HPV16 and HPV18 plasmids + IL-12 DNA) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa)
|
Yang, Z.
|
|
|
26 |
S8 |
p. viii1
|
artikel
|
| 24 |
Impact of tumor infiltrating lymphocytes (TILs) on local progression-free (LPFS) and disease-free (DFS) survival in localized high-risk soft tissue sarcoma (HR-STS) after neo-adjuvant chemotherapy (NAC) with regional hyperthermia (RHT)
|
Issels, R.D.
|
|
|
26 |
S8 |
p. viii1
|
artikel
|
| 25 |
Intranasal administration of Ff bacteriophages towards cancer therapy
|
Dor-On, E.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 26 |
Low neutrophil-to-lymphocyte ratio (NLR) may predict efficacy of pembrolizumab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)
|
Kao, H.-F.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 27 |
Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC 18961 trial
|
Michels, J.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 28 |
Mutational load by targeted next generation sequencing (NGS) panels as potential biomarker of response to checkpoint inhibitors
|
Martin-Liberal, J.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 29 |
Oncolytic adenoviruses armed with TNFα and IL-2 enable successful adoptive T-cell therapy of solid tumors
|
Parviainen, S.
|
|
|
26 |
S8 |
p. viii1
|
artikel
|
| 30 |
Optimising dendritic cell vaccines for adoptive therapy in glioblastoma
|
Adhikaree, J.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 31 |
PD-L1 IHC validation and comparison of E1L3N & SP142 mAbs in melanoma
|
Schats, K.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 32 |
PEGylated human IL-10 (AM0010) in advanced solid tumors
|
Naing, A.
|
|
|
26 |
S8 |
p. viii1
|
artikel
|
| 33 |
Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: methodology of phase 3 randomized trial
|
Harrington, K.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 34 |
Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors
|
Hu-Lieskovan, S.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 35 |
Phase I/II study of IMA950 peptide vaccine with Poly-ICLC in combination with standard therapy in newly diagnosed A2 glioblastoma: Preliminary results
|
Migliorini, D.
|
|
|
26 |
S8 |
p. viii1
|
artikel
|
| 36 |
Phase II trial of intraperitoneal (IP) MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with ovarian carcinoma (OC) with minimal or microscopic residual disease at second look laparotomy/laparoscopy
|
Conte, P.F.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 37 |
Phase I JAVELIN solid tumor trial of avelumab (MSB0010718C), an anti-PD-L1 antibody: Safety and pharmacokinetics
|
Arkenau, H.-T.
|
|
|
26 |
S8 |
p. viii1
|
artikel
|
| 38 |
Phase I trial of stereotactic body radiotherapy with concurrent fixed dose ipilimumab in metastatic melanoma: Dose limiting toxicity and abscopal effect
|
De Wolf, K.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 39 |
Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
|
Klochikhin, A.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 40 |
Platelet-derived growth factor associated protein-1: A plausible function in Gliomas
|
Yadav, S.
|
|
|
26 |
S8 |
p. viii15
|
artikel
|
| 41 |
Preclinical development of adoptive cell therapy with tumor-infiltrating lymphocytes for patients with renal cell carcinoma
|
Andersen, R.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 42 |
Preexisting immunity as a potential biomarker for clinical response to AE37 vaccination in breast cancer patients
|
Pistamaltzian, N.F.
|
|
|
26 |
S8 |
p. viii1
|
artikel
|
| 43 |
Prognostic and predictive value of CD8 + , CD4 + infiltration and KI-67 level in the post-chemotherapy residual disease in triple negative breast cancer
|
Verovkina, N.O.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 44 |
Prognostic role of neutrophil lymphocyte ratio in breast cancer: A single center study
|
Khullar, P.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 45 |
Prognostic significance of monocyte-lymphocyte ratio in mantle cell lymphoma
|
Das, C.K.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 46 |
Programmed death ligand-1 (PDL1) and CD3 co-expression in patients with advanced stage EGFR mutant NSCLC treated with EGFR tyrosine kinase inhibitors (TKI)
|
Soo, R.A.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 47 |
Risk of endocrine complications and elevated liver transaminases in patients with solid tumors treated with immune checkpoint inhibitors; A meta-analysis
|
Elhalawani, H.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 48 |
Role of functional determinants of Th17 & Treg cells in immune evasion of urothelial carcinoma of bladder
|
Sharma, A.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 49 |
Safety, pharmacokinetics and pharmacodynamics from a clinical trial with healthy volunteers using the immunotherapeutic TLR-9 agonist MGN1703
|
Zurlo, A.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 50 |
Table of Contents
|
|
|
|
26 |
S8 |
p. iv
|
artikel
|
| 51 |
Therapeutic vaccination against glioblastoma multiformae using CMV gB/pp65 eVLPs formulated with GM-CSF
|
Anderson, D.E.
|
|
|
26 |
S8 |
p. viii5
|
artikel
|
| 52 |
Title page
|
|
|
|
26 |
S8 |
p. iii
|
artikel
|
| 53 |
translational research index
|
|
|
|
26 |
S8 |
p. viii16
|
artikel
|
Tijdschrift beschrijving